Virtus Investment Advisers, LLC
Position in NAMS — NewAmsterdam Pharma Co N.V.
CIK 19481
HARTFORD, CT
Position in NAMS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$364,758
+$130,477 QoQ
Shares Held
10,763
+47.1% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#136
of 197 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Virtus Investment Advisers, LLC holds $130,556,170 across 185 Biotechnology names. NAMS ranks #158 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
29,544 | $3,349,107 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,953 | $2,996,151 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,320 | $2,693,692 | |
| 4 | MRNA |
Moderna, Inc.
|
23,300 | $1,631,699 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
47,757 | $1,594,606 | |
| 6 | PGEN |
Precigen, Inc.
|
261,322 | $1,489,535 | |
| 7 | AGIO |
Agios Pharmaceuticals, Inc.
|
39,473 | $1,464,843 | |
| 8 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
13,158 | $1,460,932 |
All Filings in NAMS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $364,758 | 10,763 | Shares | Other | 2026-08-11 | |
| 2026-03-31 | $234,281 | 7,319 | Shares | Other | 2026-05-14 | |
| 2025-12-31 | $250,541 | 7,142 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $153,888 | 5,411 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $80,969 | 4,471 | Shares | Other | 2025-08-13 | |
| 2025-03-31 | $133,935 | 6,543 | Shares | Other | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||